Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1950 2
1955 2
1956 1
1957 2
1958 2
1961 1
1965 1
1968 1
1970 3
1972 2
1973 2
1974 2
1975 2
1976 1
1977 1
1978 4
1979 4
1980 1
1982 1
1983 3
1984 3
1985 1
1986 4
1987 6
1988 3
1989 4
1990 3
1991 5
1992 4
1993 6
1994 3
1995 2
1996 1
1997 1
1998 3
1999 2
2000 4
2001 1
2002 5
2003 3
2004 5
2005 5
2006 4
2007 5
2008 13
2009 9
2010 11
2011 10
2012 5
2013 12
2014 16
2015 18
2016 21
2017 21
2018 18
2019 17
2020 14
2021 18
2022 26
2023 24
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

350 results

Results by year

Filters applied: . Clear all
The following term was not found in PubMed: Forfinski-Sarkozi
Page 1
Artificial Intelligence-Powered Assessment of Pathologic Response to Neoadjuvant Atezolizumab in Patients With NSCLC: Results From the LCMC3 Study.
Dacic S, Travis WD, Giltnane JM, Kos F, Abel J, Hilz S, Fujimoto J, Sholl L, Ritter J, Khalil F, Liu Y, Taylor-Weiner A, Resnick M, Yu H, Hirsch FR, Bunn PA Jr, Carbone DP, Rusch V, Kwiatkowski DJ, Johnson BE, Lee JM, Hennek SR, Wapinski I, Nicholas A, Johnson A, Schulze K, Kris MG, Wistuba II. Dacic S, et al. Among authors: nicholas a. J Thorac Oncol. 2023 Dec 7:S1556-0864(23)02415-2. doi: 10.1016/j.jtho.2023.12.010. Online ahead of print. J Thorac Oncol. 2023. PMID: 38070597
Overall Survival by Response to First-line Induction Treatment with Atezolizumab plus Platinum-based Chemotherapy or Placebo plus Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma.
Grande E, Bamias A, Galsky MD, Kikuchi E, Davis ID, Arranz JÁ, Rezazadeh Kalebasty A, Garcia Del Muro X, Park SH, De Giorgi U, Alekseev B, Mencinger M, Izumi K, Puente J, Li JR, Bernhard S, Nicholas A, Telliez J, De Santis M. Grande E, et al. Among authors: nicholas a. Eur Urol Open Sci. 2023 Nov 4;58:28-36. doi: 10.1016/j.euros.2023.10.002. eCollection 2023 Dec. Eur Urol Open Sci. 2023. PMID: 37954037 Free PMC article.
Author Correction: Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial.
Chaft JE, Oezkan F, Kris MG, Bunn PA, Wistuba II, Kwiatkowski DJ, Owen DH, Tang Y, Johnson BE, Lee JM, Lozanski G, Pietrzak M, Seweryn M, Byun WY, Schulze K, Nicholas A, Johnson A, Grindheim J, Hilz S, Shames DS, Rivard C, Toloza E, Haura EB, McNamee CJ, Patterson GA, Waqar SN, Rusch VW, Carbone DP; LCMC study investigators. Chaft JE, et al. Among authors: nicholas a. Nat Med. 2024 Jan;30(1):303. doi: 10.1038/s41591-023-02627-7. Nat Med. 2024. PMID: 37816821 Free PMC article. No abstract available.
A high-resolution daily global dataset of statistically downscaled CMIP6 models for climate impact analyses.
Gebrechorkos S, Leyland J, Slater L, Wortmann M, Ashworth PJ, Bennett GL, Boothroyd R, Cloke H, Delorme P, Griffith H, Hardy R, Hawker L, McLelland S, Neal J, Nicholas A, Tatem AJ, Vahidi E, Parsons DR, Darby SE. Gebrechorkos S, et al. Among authors: nicholas a. Sci Data. 2023 Sep 11;10(1):611. doi: 10.1038/s41597-023-02528-x. Sci Data. 2023. PMID: 37696836 Free PMC article.
350 results